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Abstract

This is the first study to evaluate the spectrum and prevalence of dose-predictive genetic
polymorphisms of the CYP2C9, CYP4F2 and VKORC1 loci together, in a geographically-defined,
ethnically admixed healthy adult Omani population sharing common life style/environmental factors.
Since the present day Omani population is the result of an admixture of Caucasian, African and Asian
ancestries, we compared the pharmacogenetic profile of these three loci in this population.
Interestingly, the Omani pharmacogenetic profile, in terms of allele and genotype distribution, has
values that are intermediate between Caucasians and African Americans, the African admixture further
substantiated by the presence of CYP2C9*8 allele. However, limitations and usefulness of such
comparisons warrant caution, as the data from pharmacogenetic literature do not always represent
bonafide

population

categories.

Furthermore,

definition

of

study

population

based

on

microgeographical scale would be more appropriate in pharmacogenetic research rather than the
flawed racial, ethnic or social categorizations since pharmacogenetic variation is clinal, and genetic
influences will be further altered by lifestyle and environmental factors.
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Introduction
In the current clinical practice, routine pharmacogenetic testing is performed only for a few
drugs and an important candidate is warfarin, a commonly prescribed anticoagulant with
narrow therapeutic index. Small warfarin dose variations result either in hemorrhagic or
thrombotic complications1. Initially genetic polymorphisms in cytochrome P450 2C9
[CYP2C9] and vitamin K epoxide reductase complex 1 [VKORC1] have been shown to affect
the warfarin dose and thereby influence the occurrence of complications1-4. Subsequently, a
genetic variant of CYP4F2 locus was also found to be associated with warfarin dose
variability and time to reach therapeutic international normalized ratio (INR) through a linked
polymorphism5,6. Since the risk of bleeding, due to over-anticoagulation, occurs mainly at the
initiation of warfarin therapy7, knowledge of a patient’s genotype could be beneficial in
planning an initiation protocol that is likely to avoid this complication. Accordingly, inclusion
of CYP2C9, CYP4F2 and VKORC1 genotype data in the existing algorithms is expected to
reduce the risk of bleeding during the warfarin induction phase.

Nevertheless, most pharmacogenetic models explain less than 50% of the variation in the
warfarin dose amongst treated patients. This implies that other factors (genetic, concurrent
disease, or environmental) participate in the intra and inter individual variations in warfarin
dose requirement. However, three subsequent large genome-wide association studies failed to
confirm the existence of additional genetic loci, other than CYP2C9, CYP4F2 and VKORC1810

. Therefore, the unexplained part of the variability is believed to be essentially due to life

style and environmental factors (including dietary bioavailability of vitamin K).

At the population level, significant differences are reported in the performances of dosing
algorithms between groups loosely designated as Caucasians and African Americans, with
only marginal benefit for African Americans during warfarin initiation therapy6,11. Similarly,
performance was quite variable even within the so called east Asian population groups12. Such
differences are believed to be due mainly to significant differences in the prevalence of
functional polymorphisms in the genes encoding the key enzymes involved in the
pharmacokinetic(CYP2C9 and CYP4F2) and pharmacodynamic (VKORC1) behavior of
warfarin/ vitamin K although, as mentioned above, other non-genetic factors could still
3

contribute to some extent. Given the fact that the frequency distribution of polymorphisms in
CYP2C9 and VKORC1 varies across populations, influence of these genes could affect
different proportions of individuals in a given population. Thus a clear understanding of the
spectrum and prevalence of functionally relevant mutant alleles of these loci in a given
geographically-restricted population group could help in designing targeted screening
strategies for markers of drug response. In fact it is striking to note that the present trend in
labeling populations into ethnicity/race is not accurate and hence does not represent the
bonafide genetic structure and drug response profiles of a given study population. Moreover,
since human genetic variation is greatly influenced by geography it is more appropriate to
study the genetic structuring of geographically–defined populations for evaluating the efficacy
and safety of drugs with narrow therapeutic index such as warfarin rather than using the
flawed concepts of (self identified) race/ethnicity. Accordingly, we thus undertook to analyze
the frequency distribution of warfarin dose-predictive genetic polymorphisms in the VKORC1,
CYP2C9 and CYP4F2 loci, for the first time, in a geographically defined, ethnically admixed
Omani population.

Materials & methods
Study population
The study was initiated after obtaining formal approval from the institutional ethics
committee. Study subjects were unrelated healthy adult blood donors attending the blood
bank at the Sultan Qaboos University Hospital, Muscat, Oman. A written informed consent
was obtained from each participant as per our study protocol. A total of 240 subjects (180
males and 60 females) agreed to participate. Their mean age was 28.6(+7.2 SD) years.

A 5ml blood sample was collected in tubes containing EDTA. Genomic DNA was isolated
using the semi-automated ABI PRISM™ 6100 Nucleic Acid Prep Station, [Applied
Biosystems, Foster city, CA, USA] and samples were stored at -200C pending analysis. All
the DNA polymorphisms were studied by direct sequencing of the relevant PCR- amplified
genome segment on ABI PRISM™ 3100 Genetic Analyzer (Applied Biosystems, Foster city,
CA, USA) using home-designed primers.[available on request]
4

Genotyping
CYP2C9 & CYP4F2:
DNA segments encompassing exons 3 and 7 of CYP2C9 and exon 11 of CYP4F2 genes were
amplified by PCR and the PCR products were submitted for DNA sequencing to explore the
following single nucleotide polymorphisms(SNPs); CYP2C9 *2 (430C>T), *3 (1075A>C),
*4 (1076T>C), *5 (1080C>G), *8(449G>A),*11(1003C>T) and CYP4F2*3(1297G>A)
respectively using a sequencing protocol provided by the manufacturer of the commercial kit.
(Applied Biosystems, Foster city, CA, USA)

VKORC1:
The DNA segment containing the g.-1639G>A polymorphism (rs 9923231) and 6484 C>T or
g.1173 C>T (rs 9934438) of the VKORC1 locus (GeneBank accession number AY587020)
were PCR-amplified and analyzed by DNA sequencing of the PCR product as above.

Statistical analysis:
Frequency distribution of the CYPC2C9, CYP4F2 and VKORC1 polymorphisms were
compared by chi square and Fishers exact test. A p value of < 0.05 was considered as
statistically significant. The observed allele frequencies were used in Hardy-Weinberg’s
equation for analyzing the degree of deviation, if any, between the observed and expected
genotype frequencies by using weighted least square estimates of allele frequencies and chisquare goodness-of-fit tests, using SPSS software (ver.15) for all statistical analysis.

Results
CYP2C9 allele & genotype frequencies
Amongst a total of 240 subjects enrolled, genetic polymorphisms of CYP2C9, CYP4F2, and
VKORC1 loci were analyzed in 220,(Table 1) 192(Table 2) and 157(Table 3) samples
respectively and the combined frequencies for all the three loci was available in 157
subjects(Table 4). The results obtained in this study were compiled and compared with the
data reported for the Caucasian, African American and Asian populations6. The combined
CYP2C9 mutant allele (CYP2C9 *2,*3 and *8) frequency for Omanis was 0.16, a value
intermediate between that of Caucasians and African Americans. Similarly, the frequency of
5

warfarin-sensitive homozygotes or compound heterozygotes for the CYP2C9 mutant allele
was also of intermediate value between Caucasians and African Americans/Asians. The
CYP2C9 *4, *5, and *11 alleles were not found in the studied Omani subjects [direct
sequencing of exons 3 and 7].

CYP4F2 allele & genotype frequencies
The variant allele and genotype frequencies of the CYP4F2 locus are compiled with data for
Caucasian, African American and Asian populations6. The observed CYP4F2*3 allele and
genotype frequency in Omanis was not different from that observed in Caucasians/Asians,
but was quite significantly higher (p<0.05) than that reported for African Americans (3 and
10 fold respectively).

VKORC1 allele and genotype frequencies
The frequency of the minor allele g.-1639A in Omanis showed intermediate values between
African Americans and Caucasians, but nevertheless threefold higher than African
Americans and around three fourths of the frequency reported in Caucasians6. Nevertheless,
Asians had the highest frequency of VKORC1 variant allele (1.5 to 2 fold of Caucasians and
Omanis respectively). A similar trend was noted for the homozygosity for this warfarin
sensitive VKORC1 allele.

Combined CYP2C9, CYP4F2 and VKORC1 frequencies
The combined frequency data for the CYP2C9, VKORC1 and CYP4F2 loci which allow the
prediction of probable outcome if exposed to warfarin6. In these 157 Omani subjects, for
whom we had the complete data for all the analyzed loci, individual warfarin sensitive
genotype frequency of CYP2C9 as well as VKORC1 were seen in 3.7% and 14%
respectively. However, none of these subjects were homozygous for the CYP4F2*3 allele
(Table 4), which confers relative warfarin resistance5,6. Furthermore, amongst these 157
subjects, only 2 cases (1.2%) were bearing warfarin-sensitive genotype for both CYP2C9 and
VKORC1 loci together.
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Discussion
This is the first study documenting the frequencies of CYP2C9, CYP4F2, and VKORC1 in
healthy adult Omani subjects. Oman, is located in the southeastern part of the Arabian
Peninsula with a native population of around 2 million. The Omani population consists of an
admixture of Caucasian, African and Asian ancestries. Each of these populations,
constituting the present day Omanis, had previously been shown to require a distinct average
warfarin dose corroborating with the relative prevalence of warfarin sensitive alleles.

CYP2C9
CYP2C9 is the principal drug metabolizing enzyme that catalyzes the hydroxylation of
warfarin13,14. The CYP2C9 enzyme accounts for 80%–85% of the metabolism of the
pharmacologically potent S-warfarin enantiomer. Seven principal alleles of CYP2C9,
including CYP2C9*2 (430C>T), *3 (1075A>C), *5 (1080C>G), *6 (818delA) *8(449G>A) ,
(1003C>T)*11 and (269T>C)*13 (http://www.cypalleles.ki.se)15, are associated with a
decreased metabolic efficiency of the CYP2C9 enzyme15-17. Although more than 34 different
CYP2C9 variants have been described, only two common variants, CYP2C9*2 and
CYP2C9*3 have consistently been shown to be polymorphic in various populations and have
been demonstrated to show significant clinical variability in warfarin dose requirements with
propensity for bleeding complications1-3.

Direct sequencing of the two exons of CYP2C9 was our option (instead of RFLP-based
assessment of the two SNP’s [i.e. CYP2C9*2 and *3] as, by sequencing the exons 3 and 7 of
the CYP2C9 gene, we were able to study the status of six of the seven principal alleles
responsible for significant reduction in the enzyme activity namely CYP2C9*2,*3,*5, *6,*8
and *11 alleles15-18 with the last four alleles occurring almost exclusively in Africans . This is
relevant, as the present Omani population is known to have African admixture as Zanzibar
was under Omani rulers. In our study, we observed that homozygotes and compound
hetrozygotes for the mutant CYP2C9*2,*3 and *8 alleles were present in about 3.7% of the
Omani subjects with a heterozygote rate of 24.2% (Table 1) comparable with a previous
report on Omani patients on warfarin therapy19. However, that study did not explore the
7

polymorphic state of the VKORC1 and CYP4F2 loci, which are also associated with warfarin
dose variability.

CYP4F2
The CYP4F2 locus has been shown to code the primary human liver microsomal vitamin K1
oxidase and the CYP4F2*3 allele is associated with decreased steady-state hepatic
concentrations of the enzyme with consequent reduction in the metabolism of vitamin K1 and
a higher warfarin requirement for therapeutic anticoagulant effect.

Indeed subjects

homozygous for CYP4F2*3 allele require warfarin of about 1.2mg more than the wild type
genotype5. Since CYP4F2*3 allele frequency in African American subjects is distinctly low
they are believed to benefit less from the dosing algorithms that include this variant6,20.
Furtheremore, since Omani subjects have a comparable frequency of CYP4F2*3 allele with
that of Caucasians, its effect in the algorithm will be similar, but quite marginal as we failed
to find homozygous CYP4F2*3 allele in any of the subjects bearing the warfarin sensitive
genotype for CYP2C9 and VKORC1(Table 4). On the contrary, we speculate that CYP4F2
typing will be particularly beneficial for east Asian population given the high frequency of
both the VKORC1 warfarin sensitive genotype and the relative warfarin resistant CYP4F2
*3/*3 genotype.

VKORC1
Some common SNPs of VKORC1 locus defining the VKORC1 haplotypes have been
associated with clinically significant differences in warfarin maintenance dose3. Indeed a
single SNP, either g.-1639 G>A in the VKORC1 promoter or g.1173 C>T in intron 1 behaved
as a tag SNP in distinguishing the warfarin sensitive VKORC1*2 haplotype from the other
haplotypes3,4,20. Our study revealed that this warfarin sensitive tag-SNP g.-1639A or g.1173T
was found in approximately 44% of the Omani population, with 14% in homozygous state.

Population Comparison of CYP2C9, VKORC1 and CYP4F2polymorphism
Genetic polymorphisms in the CYP2C9, VKORC1 and/or CYP4F2 loci are thus far the only
important genetic determinants for individual warfarin dose variations8,9. As the frequency
distribution of these polymorphisms in the three genes varies across populations
8

(https://www.pharmgkb.org/), the relative contribution of the CYP2C9, CYP4F2 and
VKORC1 to the warfarin dose will obviously be different among population groups21. Given
the extensive admixture of the present-day Omani population with gene flow from (east)
Africa, Europe and Asia, it is tempting to compare the prevalence data of Omanis with the
above mentioned population groups (Tables 1-3). Indeed the allele and genotype distribution
has values intermediate between Caucasians and African Americans apparently complying
with the documented Caucasian and African admixture of the Omani population22, and
noticeably by the presence of CYP2C9*8 allele in Omanis, a prevalent allele in the African
population. However, limitations and usefulness of these comparisons and interpretations
warrant caution as the terms Caucasians, African Americans and Asians used in
pharmacogenetic literature do not represent population genetic categories, but rather a flawed
concepts of racial, ethnic and social categories quite often self declared. This is an important
consideration because human genetic variation is clinal and greatly influenced by
geography23. Our study concerns a fully characterized distinct geographically-defined Omani
population group, with unbiased racial, ethnic or social considerations. Indeed, regardless of
admixture, individuals from this population share common lifestyle / environmental factors,
which are also important determinants of warfarin dose response besides genetic factors.

GENETIC INTERACTIONS
It is interesting to note that although genetic polymorphisms in CYP2C9, VKORC1 and/or
CYP4F2 are important, homozygosity or compound hetrozygosity for the major mutant
alleles in CYP2C9 [*2 and *3] and VKORC1 [g.-1639AA] contribute to warfarin sensitivity
whereas, homozygosity for the mutant allele of CYP4F2 [*3] confers relative warfarin
resistance3-5,10,14. Thus, from a population perspective, the expected contribution of the
CYP2C9 and VKORC1 on the one hand and CYP4F2 on the other will be opposite in
determining the warfarin requirement. Indeed, homozygosity for the CYP4F2*3 has
previously been associated with a relatively higher warfarin dose requirement in the
Caucasian subjects5. Nevertheless, the population prevalence of homozygosity for the mutant
allele CYP4F2*3 in all studied Caucasian populations as well as the Omani population being
similar, influence of this locus across such populations will be similar, leaving the CYP2C9
and VKORC1 loci as the main warfarin dose predictive markers in the Omani population.
9

This complies with the previous population studies wherein only CYP2C9 and VKORC1
were found to be the two major loci influencing the warfarin dose requirement8. Recently a
paper by Limdi NA et al24 concluded that warfarin-dosing algorithm incorporating VKORC1
g.-1639G>A improved dose prediction across 3 racial groups namely Asian, Black and white
subjects recruited across several countries in the cadre of IWPC. It was then concluded that
although at the population level, the contribution of VKORC1 towards warfarin dose
requirements is higher in whites than nonwhites, genotype predicts similar dose requirements
across racial groups.24

In our population, only 1.2% of Omanis showed warfarin sensitive CYP2C9 and VKORC1
genotypes together and hence were at the highest risk of bleeding complications if exposed to
warfarin. None of these subjects however possessed the warfarin relative resistance CYP4F2
genotype (*3/*3). Thus, altogether around one fourth of the Omani subjects are susceptible to
warfarin treatment- related bleeding complications as compared to one fifth of the
Caucasians based on the independent homozygosity for CYP2C9 and VKORC1 mutant
genotypes (Tables 1 & 3).

In conclusion, this study for the first time establishes the allele and genotype frequencies of
the three main genetic loci that are associated with the pharmacokinetic (CYP2C9 &
CYP4F2) and pharmacodynamic (VKORC1) variables for warfarin dose variations in a
geographically explicit manner for the Omani population.

This study represents a resource for warfarin pharmacogenetic variations in a geographicallydefined Arabian Gulf population, namely the Omanis. Since within this Gulf region, the
history of population migration and the local effective population size differ, results obtained
herein cannot be directly extrapolated to neighboring populations and requires perspective
studies with structured sampling at a microgeographic scale25. At the global level, since
many regions are still underrepresented in pharmacogenetic research, especially those like
Africa and Asia where high disease burden and diversity prevails, cost-effective and safe
pharmacologic interventions are needed.
10
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Table 1: ALLELE AND GENOTYPE FREQUENCIES FOR CYPC2C9 IN OMANI SUBJECTS AND THEIR
COMPARISON WITH OTHER POPULATION GROUPS.
(a) Allele frequencies
Allèle

Caucasian6[n=106]

Omani [n=220] Afr. American6[n=300] Asian6[n=102]

*1

0.79

0.84

0.87

0.92

*2

0.15

0.08

0.03

0.03

*3

0.06

0.07

0.02

0.04

*8

0.00

0.01

0.05

0.01

*others

0.00

0.00

0.03

0.00

Mu

0.21

0.16

0.13

0.08

+

(b)Genotype frequencies ( expected %)
Genotype
Extensive metaboliser
*1/*1

66.0(62.1)

72.1(71.1 )

75.7 (75.1)

86.3(84.9)

24.2(26.47 )

22.7(23.1)

11.8#(14.5)

3.7( 2.5)

1.7#(1.0)

2.0#(0.6)

Intermediate metaboliser
*1/*2, *1/*3, *1/*8
*others

25.5(33.4)

Poor metaboliser[Warfarin sensitive]
*2/*2, *2/*3, *3/*3
*others

8.5#(4.4)

Key: Mu – Mutant alleles (CYP2C9*2,*3, *8 &*others together), * others – (*4,*5,*6,*11&*13);
n=Number of subjects. Data from Ref. no. 6 is used for comparison
# p<0.05 when compared with Omani subjects. + Predicted Hardy-Weinberg frequencies.
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Table 2: ALLELE AND GENOTYPE FREQUENCIES FOR CYP4F2 IN NORMAL OMANI CONTROLS
AND COMPARISON WITH OTHER POPULATION GROUPS.
(a) Allele frequencies
Allele

Caucasian6

Omani

Afr. American6

Asian6

*1

0.66

0.65

0.88

0.70

*3

0.34

0.35

0.12#

0.30

(b) Observed Genotype frequencies (+expected %)
Genotype

Caucasian

Omani (n=192)

Afr. American

Asian

CYP4F2 *1/*1

42.7 (43.3)

41.0(41.6)

78.0(78) #

48.0(48.3)

CYP4F2 *1/*3

46.3(45.0)

47.9(45.6)

20.7(20.6)#

42.0(42.4)

CYP4F2 *3/*3

11.0(11.7)

11.0(12.5)

1.3(1.4)#

9.0(9.3)

Data Compiled from Ref. No. 6 is used for comparison
# p<0.05 when compared with Omani subjects.
+
Predicted Hardy-Weinberg frequencies, n=Number of subjects.
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Table 3: ALLELE AND GENOTYPE FREQUENCIES FOR VKORC1 IN NORMAL OMANI CONTROLS
AND COMPARISON WITH OTHER POPULATION GROUPS.
(a) Allele frequencies for VKORC1 (g.-1639 G>A)
Observed frequency
Allele

Caucasian6

Omani

Afr. American6

Asian6

-1639 G

0. 594

0. 683

0.892

0.333

-1639 A

0. 406

0.317

0.108

0.667

(b)Genotype frequencies for VKORC1 (g.-1639 G>A)
Observed frequency (+expected %)
Genotype

Caucasian

Omani (n=157)

Afr. American

Asian

G/G

36.8 (35.3)

40.1 (46.6)

80.3 (79.5)

22.5 (11.1)

G/A

45.3 (48.2)

45.9 (43.3)

17.7 (19.3)

21.6 (44.4)

A/A[Warfarin sensitive]

17.9 (16.5)

14.0 (10.1)

2.0 (1.2)

55.9 (44.4)

Data Compiled from Ref. No. 6 is used for comparison
+

Predicted Hardy-Weinberg frequencies, n=Number of subjects.
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Table 4: COMPARATIVE POPULATION FREQUENCIES FOR CYP2C9, VKORC1 g.-1639G>A AND
CYP4F2*3 GENOTYPE
CYP2C9

VKORC1
g.-1639G>A

CYP4F2*3
c.1297G>A

#

Caucasian
Freq. (%)

Omani [n=157] #Amer. African #Asian
Freq. (%)
Freq. (%)
Freq. (%)

Extensive
Metabolizer

G/G

G/G
G/A
A/A

12.3
9.4
0.0

13.4
12.1
0.0

47.5
11.2
0.7

4.9
3.9
3.9

G/A

G/G
G/A
A/A

11.3
16.0
3.8

11.5
19.1
1.9

10.9
4.0
0.0

10.8
6.9
1.0

A/A

G/G
G/A
A/A

5.7
5.7
1.9
66.1

4.5
4.5
1.9
72.1

0.7
0.7
0.0
75.7

26.5
21.6
6.9
86.4

G/G

G/G
G/A
A/A

4.7
4.7
0.9

7.0
3.2
0.6

15.9
4.0
0.4

3.9
2.0
2.0

G/A

G/G
G/A
A/A

3.8
5.7
0.9

4.5
5.7
1.3

2.5
0.4
0.0

2.0
0.0
1.0

A/A

G/G
G/A
A/A

1.9
2.8
0.0
25.4

0.0
1.9
0.0
24.2

0.7
0.0
0.0
23.9

0.0
1.0
0.0
11.9

G/G

G/G
G/A
A/A

0.9
3.8
0.0

0.0
0.6
0.0

0.0
0.0
0.0

1.0
1.0
0.0

G/A

G/G
G/A
A/A

2.8
0.9
0.0

0.6
1.3
0.0

0.4
0.0
0.0

0.0
0.0
0.0

A/A

G/G
G/A
A/A

0.0
0.0
0.0
8.4

0.6
0.6
0.0
3.7

0.0
0.0
0.0
0.4

0.0
0.0
0.0
2.0

Total
Intermediate
Metabolizer

Total
Poor
Metabolizer

Total
Extensive metabolizer: CYP2C9*1/*1;
Intermediate metabolizer: CYP2C9*1/variant;
Poor metabolizer: CYP2C9 variant/variant
#

Data combined from ref No 6 is used for comparison; n = number of subjects.
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